The Impact of IgG Fc-Glycosylation on Disease Dynamics in Primary Sj&#xf6;gren&apos;s Disease- Insights from the Belgian Sj&#xf6;gren&apos;s Syndrome Transition Trial

Autoimmune Disease

A systematic review of clinical trial designs and outcome measures in Sjögren's disease randomized trials

J Rheumatol

Beydon M, Nguyen Y, Gordon R, Foulquier N, Bouillot C, Hammitt KM, Bowman SJ, Mariette X, Cornec D, McCoy SS, Seror R

doi: 10.3899/jrheum.2024-1012

Further Publications Immunology

Patients' recollection about the onset of Sjögren's disease - a mixed methods study on the patients' perspective

Arthritis Res Ther

Lackner A, Dreo B, Hermann J, Zenz S, Fessler J, Thiel J, Stradner MH

doi: 10.1186/s13075-024-03404-8

Autoimmune Disease

Arterial cardiovascular outcomes and venous thromboembolism in patients with primary Sjögren's syndrome: A Danish cohort study

Rheumatology (Oxford)

Loiseau P, Mailhac A, Duhaut P, Thomsen RW

doi: 10.1093/rheumatology/keaf210

Autoimmune Disease

Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study

Lancet

Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W, TWINSS study group

doi: 10.1016/S0140-6736(24)01211-X

Further Publications Immunology

Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease

Ann Rheum Dis

Bindoli S, De Matteis A, Mitrovic S, Fautrel B, Carmona L, De Benedetti F

doi: 10.1136/ard-2024-225854

Further Publications Rheumatology

FGL-1 Modulates Inter-Organ Communication by Controlling T Cell Homeostasis during the Onset of Sjögren's Disease

Arthritis Rheumatol

Otsuka K, Ushio A, Nagao R, Matsuzawa S, Arakaki R, Fukuta K, Mouri Y, Tsunematsu T, Ishimaru N

doi: 10.1002/art.43236

Autoimmune Disease

A cross-sectional observational study of patients with sicca with salivary autoantibodies defines a potential new phenotype of Sjögren's disease

Ann Rheum Dis

Tsaliki M, Cavett J, Kurien BT, Bruxvoort C, Lewis VM, Ice JA, Dave D, Khosravani S, Grundahl K, Lessard CJ, Rasmussen A, Sivils KL, Farris AD, Koelsch KA, Scofield RH

doi: 10.1016/j.ard.2025.03.012

Immunotherapy

Development of salivary gland organoids derived from patient biopsies: a functional model of Sjögren's disease

Ann Rheum Dis

Meudec L, Goudarzi N, Silva-Saffar SE, Pascaud J, Jaulin F, Pascal Q, Lazure T, Bechara R, Mariette X, Nocturne G

doi: 10.1016/j.ard.2025.04.020

Autoimmune Disease

Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional study

Rheumatology (Oxford)

Tison A, Jousse-Joulin S, Consigny M, Moog P, Hofauer B, Hachulla E, Lamotte C, Morel J, Mouterde G, Milic V, Bootsma H, Stel A, Fisher BA, Maybury M, Baer A, DiRenzo D, Kim HR, Min HK, Lee SS, Choi SE, Alegria GC, Boisramé S, Guellec D, Cornec D, Quéré B, Jonsson M, Hammenfors D, Saraux A, Devauchelle-Pensec V

doi: 10.1093/rheumatology/keae690

Dermatology · Immunology · Rheumatology

The Impact of IgG Fc-Glycosylation on Disease Dynamics in Primary Sjögren's Disease- Insights from the Belgian Sjögren's Syndrome Transition Trial

Related content

A systematic review of clinical trial designs and outcome measures in Sjögren's disease randomized trials

Patients' recollection about the onset of Sjögren's disease - a mixed methods study on the patients' perspective

Arterial cardiovascular outcomes and venous thromboembolism in patients with primary Sjögren's syndrome: A Danish cohort study

Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study

Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease

FGL-1 Modulates Inter-Organ Communication by Controlling T Cell Homeostasis during the Onset of Sjögren's Disease

A cross-sectional observational study of patients with sicca with salivary autoantibodies defines a potential new phenotype of Sjögren's disease

Development of salivary gland organoids derived from patient biopsies: a functional model of Sjögren's disease

Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional study